Deloitte Corporate Finance acted as exclusive financial advisor to Fresenius Kabi AG on the disposal of its sterile compounding facility in Canton Massachusetts to Fagron NV

A multidisciplinary Deloitte CFA and Transaction Services team (“Deloitte”) in Frankfurt, led by Moritz Freiherr Schenck (Managing Director, CFA) and Marc Rauner (Partner, TS)  supported by Marc Schmitz, Felicia Strottmann, Alexander Völkel, Florian Herbers, Uwe Pots and Maximillian Otten successfully advised Fresenius Kabi AG (the “Company” or “Fresenius Kabi”), in the disposal of its 503B compounding facility in the United States to Fagron NV (“Fagron”). Deloitte acted as exclusive financial advisor and factbook provider to Fresenius Kabi AG on the disposal of its 503B compounding business in the United States. This divestiture is part of a strategy to focus on growth in biopharmaceuticals, medical technologies, clinical nutrition, and a broad range of injectable medicines used across the continuum of care. The transaction covers all operational aspects of the facility, including customers, suppliers, and around 80 employees, as well as a supply agreement with Fresenius Kabi.

This acquisition is an important step for Fagron in realizing their strategic objective of becoming the leading global platform for sterile outsourcing services by strengthening their geographic proximity towards existing and potential customers on the East Coast.

Deloitte’s in-depth knowledge of the pharmaceutical sector with first-class execution capabilities emphasize its competence to complete a complex and time-critical transaction successfully. Despite the challenges posed by COVID-19 and an international landscape of potential partners, Deloitte provided beside M&A advice, preparation of a Financial Fact Book extensive support during the preparation phase, due diligence phase and contract negotiations, including the communication with and management of relevant stakeholders worldwide, ultimately leading to a favourable outcome for Fresenius Kabi. Deloitte’s cross-functional setup ensured a highly efficient cross-border transaction, thereby maintaining momentum throughout the transaction.

___________________

About Fresenius Kabi AG

Fresenius Kabi Germany is one of the leading suppliers in the areas of nutrition, infusions, pharmaceuticals and medical products.

About Deloitte – Corporate Finance Advisory

As leading independent M&A advisors, we provide M&A deal execution and financial advisory services to large and mid-market corporations as well as to private equity firms globally. We offer financial advice and insight at every stage of a transaction – from consideration of strategic options to transaction execution, be it an IPO, acquisition or divestment, restructuring or fast track disposal. We pride ourselves in our independent advice to our clients.

View selected transactions completed by Corporate Finance specialists across the Deloitte Member Firm network and visit our global Deal Website